semaglutide prediabetes progression to type 2 diabetes trial Efficacy and tolerability by exposure in the PIONEER and 𝐒𝐭𝐚𝐠𝐢𝐧𝐠 𝐩𝐫𝐞𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐚𝐧𝐝 𝐭𝐲𝐩𝐞 2

Lets unpack the science and what to do next

This functionality makes it particularly effective for patients unable to control their blood sugar through diet or exercise alone

Notably, the STEP TEENS trial showed that semaglutide 2.4 mg, administered once weekly via subcutaneous injection, can be used in individuals aged 12 years and older, as adolescents with obesity treated with semaglutide experienced a significant reduction in BMI compared with placebo, along with improvements in several cardiometabolic risk factors [47]

While this means that its great for onceweekly dosing, clinically relevant levels linger for weeks after you stop

For example, if I am a patient looking to lose 10% of my body weight, the decision on which medicine to use might finally come down to price and its side effects rather than overall efficacy

Ghrelin causes hyperphagia and obesity in rats